This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Company type | Subsidiary |
---|---|
Nasdaq: KITE | |
Industry | Biopharmaceutical |
Founded | 2009 |
Founder | Arie Belldegrun and Joshua Kazam |
Fate | Acquired by Gilead Sciences |
Headquarters | , |
Key people |
|
Products | Cancer immunotherapy |
Number of employees | 2,000 |
Parent | Gilead Sciences |
Website | www.kitepharma.com |
Footnotes / references Key People,[2][3] Founder[3][1] |
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
board
was invoked but never defined (see the help page).Wright2020
was invoked but never defined (see the help page).